RUZZO, ANNAMARIA
RUZZO, ANNAMARIA
Dipartimento di Scienze Biomolecolari (DISB)
2196 Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts)
2015-01-01 Torsello, A.; Ruzzo, Annamaria; Sperduti, I.; Melucci, E.; Giacomini, E.; Mottolese, M.; Fiorino, R.; Zeuli, M.; Pescarmona, E.; Magnani, Mauro; Cognetti, F.; Garufi, C.
[Construction of an apparatus for pulsed field electrophoresis for the analysisof high molecular weight DNA]
1989-01-01 Gennarelli, M; Novelli, G; Ruzzo, Annamaria; Grianti, F; Dallapiccola, B.
A novel diffuse gastric cancer susceptibility variant in E-caderin(CDH1) intron 2: A case control study in an Italian population
2008-01-01 Nasri, S; More, H; Graziano, F; Ruzzo, Annamaria; Wilson, E; Dunbier, A; Mckinney, C; Merriman, T; Guilford, P; Magnani, Mauro; Humar, B.
A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4
2020-01-01 Campopiano, Rosa; Ferese, Rosangela; Buttari, Fabio; Femiano, Cinzia; Centonze, Diego; Fornai, Francesco; Biagioni, Francesca; Chiaravalloti, Maria Antonietta; Magnani, Mauro; Giardina, Emiliano; Ruzzo, Anna; Gambardella, Stefano
A pharmacogenetic study for clinical outcomes of high-risk stage II and stage III colon cancer patients Treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy
2017-01-01 Ruzzo, Annamaria; Galli, Fabio; Galli, Francesca; Rulli, E; Bagaloni, Irene; Lonardi, S; Bergamo, F; Ronzoni, M; Ionta, Mt; Massidda, B; Pella, N; Mucciarini, C; Labianca, R; Veltri, E; Sozzi, P; Barni, S; Nicolini, M; Biondi, E; Bramati, A; Turci, D; Buscaglia, M; Magnani, Mauro; Graziano, F.
Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
2009-01-01 Loupakis, F; Cremolini, C; Perrone, G; Stasi, I; Salvatore, L; Vincenzi, B; Ruzzo, Annamaria; Ronzoni, M; Bencardino, K; Falcone, A.
Amplificazione enzimatica specifica di una regione di DNA strettamente associata alla Corea di Huntington
1990-01-01 Novelli, G; Mandich, P; Ruzzo, Annamaria; Mannello, Ferdinando; Ajmar, F; Dallapiccola, B.
An erythroid-specific exon is present in the human hexokinase gene
1998-01-01 Ruzzo, Annamaria; Andreoni, Francesca; Magnani, Mauro
Analysis of polymorphisms in the Interleukin-1beta gene (IL-1B) and in the Interleukin-1 receptor anatagonist gene (IL-1RN) for gastric cancer susceptibility in Helicobacter Pylori (HP) negative, Italian patients. A report from the Italian Group for Genetic Research in Gastric Cancer (IGGRGC)
2004-01-01 Ruzzo, Annamaria; Pizzagalli, F; Graziano, F; Santini, D; Catalano, V; Scartozzi, M; Ficarelli, R; Bearzl, I; Cascinu, S; Magnani, Mauro
ANALYSIS OF PTEN EXPRESSION AND KRAS MUTATIONS ON PRIMARIES (PRIM) AND METASTASES (METS) TO PREDICT BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
2008-01-01 Loupakis, F; Pollina, L; Ruzzo, Annamaria; Masi, G; Cremolini, C; Scartozzi, M; Floriani, I; Santini, D; Cascinu, S; Falcone, A.
Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization
1996-01-01 Colosimo, A; Calabrese, G; Gennarelli, M; Ruzzo, Annamaria; Sangiuolo, F; Magnani, Mauro; Palka, G; Novelli, G; Dallapiccola, B.
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients
2009-01-01 Ruzzo, Annamaria; Cremolini, C; Loupakis, F; Fornaro, L; Santini, D; Vincenzi, B; Canestrari, E; Magnani, Mauro; Falcone, A; Graziano, F.
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer
2002-01-01 Humar, B; Graziano, F; Cascinu, S; Catalano, V; Ruzzo, Annamaria; Magnani, Mauro; Toro, T; Burchill, T; Futschik, Me; Merriman, T; Guilford, P.
Association of Thymidylate Synthase Polymorphisms with Gastric Cancer Susceptibility
2004-01-01 Graziano, F; Kawakami, K; Watanabe, G; Ruzzo, Annamaria; Humar, B; Santini, D; Catalano, V; Ficarelli, R; Merriman, T; Panunzi, S; Testa, E; Cascinu, S; Bearzi, I; Tonini, G; Magnani, Mauro
ASSOCIATION OF THYMIDYLATHE SYNTHASE POLYMORPHISMS WITH GASTRIC CANCER SUSCEPTIBILITY
2004-01-01 Graziano, F; Kawakami, K; Watanabe, G; Ruzzo, Annamaria; Santini, D; Catalano, V; Ficarelli, R; Humar, B; Merriman, T; Guilford, P; Testa, E; Galizia, E; Magnani, Mauro; Cascinu, S.
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
2018-01-01 Wong, Gabrielle S; Zhou, Jin; Bin Liu, Jie; Wu, Zhong; Xu, Xinsen; Li, Tianxia; Xu, David; Schumacher, Steven E; Puschhof, Jens; Mcfarland, James; Zou, Charles; Dulak, Austin; Henderson, Les; Xu, Peng; O'Day, Emily; Rendak, Rachel; Liao, Wei-Li; Cecchi, Fabiola; Hembrough, Todd; Schwartz, Sarit; Szeto, Christopher; Rustgi, Anil K; Wong, Kwok-Kin; Diehl, J Alan; Jensen, Karin; Graziano, Francesco; Ruzzo, Annamaria; Fereshetian, Shaunt; Mertins, Philipp; Carr, Steven A; Beroukhim, Rameen; Nakamura, Kenichi; Oki, Eiji; Watanabe, Masayuki; Baba, Hideo; Imamura, Yu; Catenacci, Daniel; Bass, Adam J
BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients
2008-01-01 Loupakis, F; Fornaro, L; Graziano, F; Santini, D; Cremolini, C; Stasi, I; Baldi, Gg; Salvatore, L; Vasile, E; Masi, G; Cupini, S; Canestrari, E; Ruzzo, Annamaria; Vincenzi, B; Tonini, G; Magnani, Mauro; Falcone, A.
BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS
2009-01-01 Cremolini, C; Loupakis, F; Perrone, G; Ruzzo, Annamaria; Rulli, E; Garavaglia, D; Bencardino, K; Fornaro, L; Vincenzi, B; Stasi, I; Masi, G; Baldi, G; Floriani, I; Graziano, F; Falcone, A.
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
2009-01-01 Cremolini, C; Loupakis, F; Perrone, G; Ruzzo, Annamaria; Rulli, E; Bencardino, K; Vincenzi, B; Salvatore, L; Graziano, F; Falcone, A.
BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OFBENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILDTYPEMETASTATIC COLORECTAL CANCER (MCRC) PATIENTS
2009-01-01 Cremolini, C; Loupakis, F; Perrone, G; Ruzzo, Annamaria; Rulli, E; Garavaglia, D; Bencardino, K; Fornaro, L; Vincenzi, B; Stasi, I; Masi, G; Santini, D; Vasile, E; Salvatore, L; Baldi, Gg; Spoto, C; Tonini, G; Floriani, I; Graziano, F; Falcone, A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 2196 Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts) | 1-gen-2015 | Torsello, A.; Ruzzo, Annamaria; Sperduti, I.; Melucci, E.; Giacomini, E.; Mottolese, M.; Fiorino, R.; Zeuli, M.; Pescarmona, E.; Magnani, Mauro; Cognetti, F.; Garufi, C. | |
| [Construction of an apparatus for pulsed field electrophoresis for the analysisof high molecular weight DNA] | 1-gen-1989 | Gennarelli, M; Novelli, G; Ruzzo, Annamaria; Grianti, F; Dallapiccola, B. | |
| A novel diffuse gastric cancer susceptibility variant in E-caderin(CDH1) intron 2: A case control study in an Italian population | 1-gen-2008 | Nasri, S; More, H; Graziano, F; Ruzzo, Annamaria; Wilson, E; Dunbier, A; Mckinney, C; Merriman, T; Guilford, P; Magnani, Mauro; Humar, B. | |
| A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4 | 1-gen-2020 | Campopiano, Rosa; Ferese, Rosangela; Buttari, Fabio; Femiano, Cinzia; Centonze, Diego; Fornai, Francesco; Biagioni, Francesca; Chiaravalloti, Maria Antonietta; Magnani, Mauro; Giardina, Emiliano; Ruzzo, Anna; Gambardella, Stefano | |
| A pharmacogenetic study for clinical outcomes of high-risk stage II and stage III colon cancer patients Treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy | 1-gen-2017 | Ruzzo, Annamaria; Galli, Fabio; Galli, Francesca; Rulli, E; Bagaloni, Irene; Lonardi, S; Bergamo, F; Ronzoni, M; Ionta, Mt; Massidda, B; Pella, N; Mucciarini, C; Labianca, R; Veltri, E; Sozzi, P; Barni, S; Nicolini, M; Biondi, E; Bramati, A; Turci, D; Buscaglia, M; Magnani, Mauro; Graziano, F. | |
| Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients | 1-gen-2009 | Loupakis, F; Cremolini, C; Perrone, G; Stasi, I; Salvatore, L; Vincenzi, B; Ruzzo, Annamaria; Ronzoni, M; Bencardino, K; Falcone, A. | |
| Amplificazione enzimatica specifica di una regione di DNA strettamente associata alla Corea di Huntington | 1-gen-1990 | Novelli, G; Mandich, P; Ruzzo, Annamaria; Mannello, Ferdinando; Ajmar, F; Dallapiccola, B. | |
| An erythroid-specific exon is present in the human hexokinase gene | 1-gen-1998 | Ruzzo, Annamaria; Andreoni, Francesca; Magnani, Mauro | |
| Analysis of polymorphisms in the Interleukin-1beta gene (IL-1B) and in the Interleukin-1 receptor anatagonist gene (IL-1RN) for gastric cancer susceptibility in Helicobacter Pylori (HP) negative, Italian patients. A report from the Italian Group for Genetic Research in Gastric Cancer (IGGRGC) | 1-gen-2004 | Ruzzo, Annamaria; Pizzagalli, F; Graziano, F; Santini, D; Catalano, V; Scartozzi, M; Ficarelli, R; Bearzl, I; Cascinu, S; Magnani, Mauro | |
| ANALYSIS OF PTEN EXPRESSION AND KRAS MUTATIONS ON PRIMARIES (PRIM) AND METASTASES (METS) TO PREDICT BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) | 1-gen-2008 | Loupakis, F; Pollina, L; Ruzzo, Annamaria; Masi, G; Cremolini, C; Scartozzi, M; Floriani, I; Santini, D; Cascinu, S; Falcone, A. | |
| Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization | 1-gen-1996 | Colosimo, A; Calabrese, G; Gennarelli, M; Ruzzo, Annamaria; Sangiuolo, F; Magnani, Mauro; Palka, G; Novelli, G; Dallapiccola, B. | |
| Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients | 1-gen-2009 | Ruzzo, Annamaria; Cremolini, C; Loupakis, F; Fornaro, L; Santini, D; Vincenzi, B; Canestrari, E; Magnani, Mauro; Falcone, A; Graziano, F. | |
| Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer | 1-gen-2002 | Humar, B; Graziano, F; Cascinu, S; Catalano, V; Ruzzo, Annamaria; Magnani, Mauro; Toro, T; Burchill, T; Futschik, Me; Merriman, T; Guilford, P. | |
| Association of Thymidylate Synthase Polymorphisms with Gastric Cancer Susceptibility | 1-gen-2004 | Graziano, F; Kawakami, K; Watanabe, G; Ruzzo, Annamaria; Humar, B; Santini, D; Catalano, V; Ficarelli, R; Merriman, T; Panunzi, S; Testa, E; Cascinu, S; Bearzi, I; Tonini, G; Magnani, Mauro | |
| ASSOCIATION OF THYMIDYLATHE SYNTHASE POLYMORPHISMS WITH GASTRIC CANCER SUSCEPTIBILITY | 1-gen-2004 | Graziano, F; Kawakami, K; Watanabe, G; Ruzzo, Annamaria; Santini, D; Catalano, V; Ficarelli, R; Humar, B; Merriman, T; Guilford, P; Testa, E; Galizia, E; Magnani, Mauro; Cascinu, S. | |
| Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition | 1-gen-2018 | Wong, Gabrielle S; Zhou, Jin; Bin Liu, Jie; Wu, Zhong; Xu, Xinsen; Li, Tianxia; Xu, David; Schumacher, Steven E; Puschhof, Jens; Mcfarland, James; Zou, Charles; Dulak, Austin; Henderson, Les; Xu, Peng; O'Day, Emily; Rendak, Rachel; Liao, Wei-Li; Cecchi, Fabiola; Hembrough, Todd; Schwartz, Sarit; Szeto, Christopher; Rustgi, Anil K; Wong, Kwok-Kin; Diehl, J Alan; Jensen, Karin; Graziano, Francesco; Ruzzo, Annamaria; Fereshetian, Shaunt; Mertins, Philipp; Carr, Steven A; Beroukhim, Rameen; Nakamura, Kenichi; Oki, Eiji; Watanabe, Masayuki; Baba, Hideo; Imamura, Yu; Catenacci, Daniel; Bass, Adam J | |
| BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients | 1-gen-2008 | Loupakis, F; Fornaro, L; Graziano, F; Santini, D; Cremolini, C; Stasi, I; Baldi, Gg; Salvatore, L; Vasile, E; Masi, G; Cupini, S; Canestrari, E; Ruzzo, Annamaria; Vincenzi, B; Tonini, G; Magnani, Mauro; Falcone, A. | |
| BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS | 1-gen-2009 | Cremolini, C; Loupakis, F; Perrone, G; Ruzzo, Annamaria; Rulli, E; Garavaglia, D; Bencardino, K; Fornaro, L; Vincenzi, B; Stasi, I; Masi, G; Baldi, G; Floriani, I; Graziano, F; Falcone, A. | |
| BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients | 1-gen-2009 | Cremolini, C; Loupakis, F; Perrone, G; Ruzzo, Annamaria; Rulli, E; Bencardino, K; Vincenzi, B; Salvatore, L; Graziano, F; Falcone, A. | |
| BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OFBENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILDTYPEMETASTATIC COLORECTAL CANCER (MCRC) PATIENTS | 1-gen-2009 | Cremolini, C; Loupakis, F; Perrone, G; Ruzzo, Annamaria; Rulli, E; Garavaglia, D; Bencardino, K; Fornaro, L; Vincenzi, B; Stasi, I; Masi, G; Santini, D; Vasile, E; Salvatore, L; Baldi, Gg; Spoto, C; Tonini, G; Floriani, I; Graziano, F; Falcone, A. |